A Study of a Rilpivirine Extended-Release Suspension in Healthy Participants
- First Posted Date
- 2021-11-09
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 126
- Registration Number
- NCT05112939
- Locations
- π³π±
PRA Health Sciences, Groningen, Netherlands
A Study to Evaluate the Effect of Hepatic Impairment on Lazertinib (JNJ-73841937)
- First Posted Date
- 2021-11-09
- Last Posted Date
- 2023-10-12
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 16
- Registration Number
- NCT05112952
- Locations
- π©πͺ
CRS Clinical Research Services Kiel GmbH, Kiel, Germany
π©πͺAPEX GmbH, Munchen, Germany
A Standard of Care Study of Patients With Major Depressive Disorder Who Have Had an Inadequate Response to a Selective Serotonin Reuptake/Serotonin-Norepinephrine Reuptake Inhibitor Antidepressant
- First Posted Date
- 2021-11-05
- Last Posted Date
- 2023-11-08
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 7
- Registration Number
- NCT05109195
- Locations
- πΊπΈ
The University of Pittsburgh of the Commonwealth System of Higher Education, Pittsburgh, Pennsylvania, United States
πΊπΈUniversity of California San Francisco, San Francisco, California, United States
π¬π§Warneford Hospital, Oxford, United Kingdom
A Study to Determine the Abuse Potential of Seltorexant Compared to Suvorexant and Zolpidem
- Conditions
- Interventions
- First Posted Date
- 2021-11-03
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 127
- Registration Number
- NCT05106153
- Locations
- πΊπΈ
Altasciences Inc., Overland Park, Kansas, United States
A Long-term Extension Study of Ustekinumab in Pediatric Participants
- Conditions
- Interventions
- First Posted Date
- 2021-10-25
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 151
- Registration Number
- NCT05092269
- Locations
- π¦π·
Centro de Investigaciones Medicas Tucuman, San Miguel De Tucuman, Argentina
π§πͺHuderf, Bruxelles, Belgium
π§πͺCliniques Universitaires Saint Luc, Bruxelles, Belgium
A Study of Guselkumab and Risankizumab in Healthy Participants and Participants With Psoriatic Arthritis
- Conditions
- Interventions
- First Posted Date
- 2021-10-19
- Last Posted Date
- 2022-07-26
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 11
- Registration Number
- NCT05083078
- Locations
- π¦πΉ
Medical University Graz, Graz, Austria
A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2021-10-19
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 587
- Registration Number
- NCT05083169
- Locations
- πΊπΈ
Emory University - Winship Cancer Institute, Atlanta, Georgia, United States
πΊπΈWest Penn Hospital, Pittsburgh, Pennsylvania, United States
πΊπΈUniversity of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
A Study of Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis
- First Posted Date
- 2021-10-19
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 60
- Registration Number
- NCT05083182
- Locations
- π©π°
Aarhus Universitetshospital, Arhus, Denmark
π©π°Odense Universitets Hospital, Odense, Denmark
π«π·CHU de Caen, Caen, France
A Study of Lazertinib (JNJ-73841937) in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2021-10-13
- Last Posted Date
- 2022-06-27
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 20
- Registration Number
- NCT05076877
- Locations
- πΊπΈ
PRA Health Sciences, Salt Lake City, Utah, United States
A Study of Guselkumab and Golimumab Combination Therapy in Participants With Active Psoriatic Arthritis
- Conditions
- Interventions
- First Posted Date
- 2021-10-08
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 91
- Registration Number
- NCT05071664
- Locations
- πΊπΈ
Great Lakes Center of Rheumatology, Lansing, Michigan, United States
πΊπΈClinvest, Springfield, Missouri, United States
πΊπΈJacobi Medical Center, Bronx, New York, United States